<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020357</url>
  </required_header>
  <id_info>
    <org_study_id>NIH-R01HL098045</org_study_id>
    <secondary_id>R01HL098045</secondary_id>
    <nct_id>NCT01020357</nct_id>
  </id_info>
  <brief_title>Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study</brief_title>
  <acronym>CAP-S</acronym>
  <official_title>Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apnea of prematurity is a common condition that is usually treated with methylxanthines.
      Methylxanthines are adenosine receptor blockers that have powerful influences on the central
      nervous system. However, little is known about the long-term effects of methylxanthines on
      the developing brain.

      The Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study is a sub-study of the main Caffeine
      for Apnea of Prematurity (CAP) trial, an international placebo-controlled randomized trial of
      methylxanthine therapy for apnea of prematurity. This sub-study is designed to take advantage
      of this cohort of ex-premature, 5-7 year old children who were randomized at birth to receive
      either caffeine or placebo, and are currently receiving detailed neurocognitive and
      behavioral assessments in the CAP trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of methylxanthines as therapy for apnea of prematurity may be a double-edged sword.
      Although widely-used, and efficacious for treatment of apnea of prematurity, long-term drug
      effects have not been rigorously studied. Neonatal methylxanthine therapy may have long-term
      impacts on sleep organization and ventilatory control. The CAP trial, funded by the Canadian
      Institutes of Health Research, was initiated due to the paucity of well-controlled data on
      the long-term effects of methylxanthines in preterm infants. The initial CAP trial was a
      multicenter, randomized, placebo-controlled trial of caffeine vs placebo as treatment for
      apnea of prematurity with follow-up to a corrected age of 18 months. 2,006 infants were
      enrolled. The CAP trial found that methylxanthines reduced the rates of bronchopulmonary
      dysplasia (BPD) and cerebral palsy (CP), and did not affect mortality. However, concerns
      remain regarding long-term sequelae of methylxanthine use. The Canadian Institutes of Health
      Research have therefore funded further follow-up of the entire CAP trial cohort to age 5
      years, corrected for prematurity. The key objectives of this study are to examine the impact
      of methylxanthines on neurocognition and behavior. This ongoing parent study provides an
      opportunity to determine potential long-term effects of methylxanthines on sleep disorders,
      and to correlate these findings with daytime functioning. Our overall hypothesis is that
      methylxanthine use in preterm infants, while beneficial in the short term, results in
      longstanding abnormalities in the regulation of sleep, and breathing during sleep.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aim 1: The primary outcome is the mean actual sleep time as measured by actigraphy, between subjects who received caffeine vs placebo.</measure>
    <time_frame>5-7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 2: The primary outcome is the apnea hypopnea index (AHI) between subjects who received caffeine vs placebo.</measure>
    <time_frame>5-7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 3: The primary outcome is the correlation between full-scale IQ from the Wechsler Preschool and Primary Scale of Intelligence (measured in the CAP trial rather than directly from this protocol), sleep time and AHI.</measure>
    <time_frame>5-7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire data: National Sleep Foundation (NSF) and Pediatric Sleep Questionnaire (PSQ) scores</measure>
    <time_frame>5-7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polysomnography data: Sleep architecture, arousal index, central apnea index, SpO2 and periodic limb movement index.</measure>
    <time_frame>5-7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Apnea of Prematurity</condition>
  <arm_group>
    <arm_group_label>caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine citrate injection</intervention_name>
    <description>Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.</description>
    <arm_group_label>caffeine</arm_group_label>
    <other_name>CafCit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 5-7 years who are enrolled in the CAP trial.

          -  Parental/guardian permission (informed consent) and if appropriate, child assent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole Marcus, M.B.B.Ch.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Hospital for Women</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006 May 18;354(20):2112-21.</citation>
    <PMID>16707748</PMID>
  </reference>
  <reference>
    <citation>Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007 Nov 8;357(19):1893-902.</citation>
    <PMID>17989382</PMID>
  </reference>
  <results_reference>
    <citation>Marcus CL, Meltzer LJ, Roberts RS, Traylor J, Dix J, D'ilario J, Asztalos E, Opie G, Doyle LW, Biggs SN, Nixon GM, Narang I, Bhattacharjee R, Davey M, Horne RS, Cheshire M, Gibbons J, Costantini L, Bradford R, Schmidt B; Caffeine for Apnea of Prematurityâ€“Sleep Study. Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. Am J Respir Crit Care Med. 2014 Oct 1;190(7):791-9. doi: 10.1164/rccm.201406-1092OC.</citation>
    <PMID>25171195</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcus CL, Traylor J, Biggs SN, Roberts RS, Nixon GM, Narang I, Bhattacharjee R, Davey MJ, Horne RS, Cheshire M, Gibbons KJ, Dix J, Asztalos E, Doyle LW, Opie GF, D'ilario J, Costantini L, Bradford R, Schmidt B. Feasibility of comprehensive, unattended ambulatory polysomnography in school-aged children. J Clin Sleep Med. 2014 Aug 15;10(8):913-8. doi: 10.5664/jcsm.3970.</citation>
    <PMID>25126039</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preterm infants</keyword>
  <keyword>very low birthweight</keyword>
  <keyword>apnea of prematurity</keyword>
  <keyword>methylxanthines</keyword>
  <keyword>sleep disturbance</keyword>
  <keyword>obstructive sleep apnea syndrome</keyword>
  <keyword>polysomnography</keyword>
  <keyword>sleep disruption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

